Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novartis AG (CH:NOVN – Research Report) and Biophytis SA (DE:6XB – Research Report).
Biophytis SA (DE:6XB)
In a report issued on March 22, Nicolas Pauillac from Kepler Capital maintained a Sell rating on Biophytis SA, with a price target of EUR0.01. The company’s shares closed last Thursday at EUR0.01.
According to TipRanks.com, Pauillac is ranked #2108 out of 8763 analysts.
Biophytis SA has an analyst consensus of Moderate Sell, with a price target consensus of EUR0.01.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
